BusinessAI imageIM Cannabis Surges 245%, XRTX Gains 12% on FDA Trial Plans
Biotech stocks drew attention Friday with IM Cannabis (IMCC) soaring over 245% despite no new company-specific news. XORTX (XRTX) rose about 12% following its announcement to submit an FDA Investigational New Drug (IND) application for the XRX-OXY-102 trial. Other stocks like SILO and BFRI were also noted but without specific details.
Rttnews·




